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Effect of Cardiac Resynchronization Therapy on
Functional Mitral Regurgitation in Heart Failure
Patrizio Lancellotti, MD, Pierre Mélon, MD, Natzi Sakalihasan, MD, André Waleffe, MD,
Christophe Dubois, MD, Michel Bertholet, MD, and Luc A. Piérard, MD
Cardiac resynchronization therapy (CRT) reduces
functional mitral regurgitation (MR) at rest. This study
assessed exercise-induced changes in MR in patients
with heart failure who were helped by CRT. The de-
terminants of these exercise-induced changes in MR
were analyzed in asynchronous and resynchronized
left ventricles. 2004 by Excerpta Medica Inc.
(Am J Cardiol 2004;94:1462–1465)
Cardiac resynchronization therapy (CRT) with biven-tricular pacing has emerged as a new approach for
treating patients with heart failure and significant ven-
tricular conduction delay and/or dyssynchrony.1–3 CRT
improves left ventricular systolic and diastolic function4
and clinical status5 and reduces functional mitral regur-
gitation (MR).6 Whether CRT significantly affects exer-
cise-induced changes in MR has never been investigated.
This study examined the effects of CRT on MR and
assessed the determinants of exercise-induced changes in
MR under biventricular pacing.
• • •
This prospective study included 27 consecutive pa-
tients with heart failure who were clinically helped by
biventricular pacing. Before CRT implantation, all were
in New York Heart Association class III and had left
ventricular ejection fractions 35%, functional MR,
were in sinus rhythm, had QRS duration 140 ms, and
had interventricular delay (the time interval between
aortic and pulmonary valve opening) 50 ms. All pa-
tients underwent quantitative exercise Doppler echocar-
diography with and without active CRT. The causes of
heart failure were idiopathic dilated cardiomyopathy in 9
patients and ischemic heart disease in 18. The protocol
was approved by the human ethical committee of our
university hospital, and all patients gave informed con-
sent.
A symptom-limited graded bicycle exercise test
was performed in a semisupine position on a tilting
exercise table. After an initial workload of 25 W
maintained for 2 minutes, the workload was increased
every 2 minutes by 25 W. Blood pressure and 12-lead
electrocardiograms were recorded every 2 minutes.
Two-dimensional and Doppler echocardiographic re-
cordings were available throughout the test.
Baseline and exercise echocardiographic studies
were performed 45 16 days after implantation of the
CRT system using the phased-array Acuson Sequoia
(Siemens AG, Munich, Germany) or VIVID 7 (GE
Healthcare, Little Chalfont, United Kingdom) imaging
device. In 17 patients, after data acquisition during
active CRT (CRT on), pacing was interrupted during
30 minutes before data acquisition during intrinsic
conduction (CRT off). In the other 10 patients, data
were first acquired with CRT off. All echocardio-
graphic and Doppler recordings were obtained in dig-
ital format and stored on optical discs for off-line
analysis. For each measurement, 3 cardiac cycles
were averaged. The quantitation of MR was per-
formed by the quantitative Doppler method using mi-
tral and aortic stroke volumes and the proximal isove-
locity surface area method, as previously described.7,8
The results of these 2 methods were averaged, allow-
ing the calculation of regurgitant volume and the
effective regurgitant orifice (ERO). Left ventricular
end-diastolic and end-systolic volumes and ejection
fractions were measured by the bi-apical Simpson disk
method. The left ventricular dP/dt was estimated from
the steepest increasing segment of the continuous-
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wave Doppler regurgitant jet, as previously de-
scribed.9 Valvular tenting area was obtained from the
parasternal long-axis view at mid-systole and mea-
sured the area enclosed between the annular plane and
the mitral leaflets.10,11
All patients received biventricular pacing devices for
CRT, with a right ventricular apical lead and left ven-
tricular pacing electrodes positioned through the coro-
nary sinus in a left ventricular epicardial vein. This
coronary sinus lead was placed in a lateral position in 21
patients (77%), in a posterior position in 4 patients, and
in an anterior position in 2 patients. The device was
programmed in DDD mode with a fixed atrioventricular
delay.
Data are expressed as means  1 SD. Paired data
were analyzed with Wilcoxon’s signed-rank test (STA-
TISTICA, version 5, StatSoft, Inc.,
Tulsa, Oklahoma). A p value of0.05
was considered significant. Linear re-
gression analysis was applied to calcu-
late the correlations between ERO at
rest and at exercise and the percentage
of increase in left ventricular dP/dt and
changes in mitral valvular deforma-
tion. The reproducibility of echocar-
diographic measurements has been
previously published.7,11
No patient included was pacing de-
pendent. At the time of echocardiogra-
phy, all patients were in sinus rhythm
and had, by definition, an improve-
ment of 1 New York Heart Associ-
ation class. The QRS duration de-
creased from 160  15 ms at baseline
to 139  22 ms (p 0.001) under
biventricular pacing.
CRT-induced changes in echocar-
diographic parameters are listed in
Table 1. During biventricular pacing,
heart rate did not change, left ven-
tricular end-diastolic and end-sys-
tolic volumes decreased (p 0.01),
left ventricular systolic function as
estimated by left ventricular dP/dt and ejection frac-
tion improved, and transtricuspid pressure gradient
and the severity of MR decreased. ERO decreased in
all patients (p  0.00001). CRT-induced changes in
ERO were correlated with the percentage of increase
in left ventricular dP/dt (r  0.72, p  0.00003).
With CRT on, functional MR was correlated with the
mitral systolic tenting area (r  0.65, p  0.0002),
whereas the correlation was not significant with CRT
off (r  0.37, p  NS). Left ventricular dP/dt was not
related to tenting area in any mode.
CRT-induced changes in echocardiographic parame-
ters during exercise are listed in Table 2. Exercise dura-
tion was greater with CRT on. During testing, heart rate
increases from at rest to peak exercise were not affected
by CRT. Compared with CRT off, changes in left ven-
tricular end-diastolic and end-systolic volumes and ejec-
tion fraction observed at rest with CRT on were main-
tained at exercise (CRT off vs CRT on, p0.05). During
exercise and in the 2 pacing conditions, left ventricular
end-diastolic volume remained unchanged, whereas end-
systolic volume decreased (p 0.001) and ejection frac-
tion increased (p 0.0001). Although the transtricuspid
pressure gradient increased in the 2 modes during exer-
cise, the increment was less with CRT on (p  0.0001).
During exercise, ERO increased in all patients with
CRT off from 22 10 (range 11 to 44) to 37 12 mm2
(range 16 to 66; p 0.001). With CRT on, ERO in-
creased in 25 patients from 12 7 mm2 at rest (range 2
to 24) to 20  8 mm2 during exercise (range 8 to 33; p
 0.0015) and decreased in the 2 remaining patients.
The increase in ERO was less during CRT on (p 
0.00002; Figure 1). During exercise, left ventricular
dP/dt increased in all patients, whatever the pacing
mode. With CRT off, exercise-induced changes in ERO
FIGURE 1. Patient exercise-induced changes in ERO with CRT off
and CRT on. ERO increased in all but 2 patients with CRT on.
However, the increase in ERO was less with CRT on.




Heart rate (beats/min) 71  7 70  8 NS
End-diastolic volume (ml) 203  37 197  35 0.0028
End-systolic volume (ml) 145  33 136  29 0.0003
Left ventricular ejection fraction (%) 29  5 31  4 0.0017
Effective regurgitant orifice (mm2) 22  10 13  7 0.00001
Left ventricular dP/dt (mm Hg/s) 572  107 853  154 0.00065
Transtricuspid pressure gradient (mm Hg) 34  9 25  8 0.00022




Heart rate (beats/min) 113  8 115  9 NS
Test duration (minutes) 4.4  1.1 4.9  0.9 0.0027
Load (W) 61  13 70  16 0.02
End-diastolic volume (ml) 200  36 194  31 0.023
End-systolic volume (ml) 136  28 126  23 0.0007
Left ventricular ejection fraction (%) 32  4 35  5 0.0005
Effective regurgitant orifice (mm2) 37  12 19  8 0.00001
Left ventricular dP/dt (mm Hg/s) 675  123 1,009  197 0.0004
Transtricuspid pressure gradient (mm Hg) 54  12 37  8 0.0001
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were strongly related to the percentage of increase in left
ventricular dP/dt (r  0.79, p 0.00001) (Figure 2),
whereas no correlation was observed with CRT on (r 
0.23, p  NS; Figure 2). In contrast, exercise-induced
changes in ERO were strongly related to changes in
systolic tenting area with CRT on (r 0.73, p 0.0009)
but not during CRT off (r  0.12, p  NS; Figure 3).
Figure 4 shows an example of the effects of CRT on MR
at rest and during exercise.
• • •
The present study is the first to
quantitatively assess the effects of
CRT on MR during exercise. Biven-
tricular pacing significantly reduces
MR severity at rest and during exer-
cise and its dynamic component,
corresponding to exercise-induced
changes in MR. At rest, the reduction
of MR is mediated by an appropriate
increase in left ventricular dP/dt,
which facilitates effective mitral
valve closure. The determinants of
dynamic MR are different in syn-
chronized versus nonsynchronized
left ventricles. In synchronized left
ventricles, exercise-induced in-
creases in MR are related to changes
in mitral valvular deformation, as es-
timated by the systolic tenting area.
In nonsynchronized left ventricles,
exercise-induced increases in MR
are more specifically determined by
inadequate increases in mitral clos-
ing force, as estimated by left ven-
tricular dP/dt.
In this study, CRT reduced the
degree of dynamic MR in all pa-
tients. At exercise, an increase in
ERO by 13 mm2 was observed in
14 patients with CRT off but in only
4 patients with CRT on. Changes in
ERO were related to the percentage
of increase in left ventricular dP/dt
during exercise with CRT off but not
with CRT on. Thus, in nonsynchro-
nized patients, exercise-induced
changes in mitral closing force rep-
resent the major determinant of ex-
ercise-induced changes in MR. The
CRT-induced improvement of left
ventricular synchronicity is probably
maintained during exercise and
might explain why there was no re-
lation between residual exercise-in-
duced changes in MR and increases
in left ventricular dP/dt. Thus, in
synchronized patients, residual dy-
namic MR is mainly determined by
an increase in tethering forces in-
duced by changes in mitral valvular
deformation.
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Survey of the Use of Organic Nitrates for the
Treatment of Chronic Congestive Heart Failure in the
United States
Fahed Bitar, MD, Mohammed W. Akhter, MD, Salman Khan, MD, Harpreet Singh, MD,
and Uri Elkayam, MD
A survey of members of the Heart Failure Society of
America revealed that despite their lack of approval
by the United States Food and Drug Administration,
nitrates are widely used in patients with chronic con-
gestive heart failure (CHF). Most members reported
using nitrates in patients with ischemic (90%) and
nonischemic (81%) causes of chronic CHF, especially
those with symptomatic CHF (43% reported using
nitrates in >50% of their patients with ischemic and
25% with nonischemic causes). Ninety-six percent re-
ported using nitrates to reduce symptoms, 74% for
hemodynamic improvement, 65% for better exercise
tolerance, and only 14% for left ventricular reversed
remodeling. Nitrates were always combined with hy-
dralazine in 25% of patients and occasionally com-
bined with hydralazine in 67%. 2004 by Excerpta
Medica Inc.
(Am J Cardiol 2004;94:1465–1468)
Organic nitrates were the first oral vasodilatoryagents to be evaluated for the treatment of pa-
tients with chronic congestive heart failure (CHF).1,2
Early studies demonstrated beneficial hemodynamic
effects,3,4 reduction of symptoms, better exercise tol-
erance,1,2 and, in combination with hydralazine, a
superior effect on survival compared with placebo.2
Despite these data and because of a lack of larger scale
studies, the use of nitrates for the treatment of patients
with CHF has not been approved by the United States
Food and Drug Administration. Despite this lack of
approval, information from recent clinical trials have
consistently suggested the widespread use of nitrates
in the treatment of patients with CHF.3–5 The purpose
of the present study was to evaluate the attitudes of
physician members of the Heart Failure Society of
America regarding the use of nitrates in the manage-
ment of chronic CHF in the United States.
• • •
We obtained information about the use of nitrates
in chronic CHF in the United States by sending ques-
tionnaires to 1,348 members of the Heart Failure So-
ciety of America with addresses in the United States.
Responses were collected over the next 3 months
(from March to May 2001). A database was created
using Excel software (Microsoft Corporation, Red-
mond, Washington). Data were analyzed using Excel
applications. The results were expressed as percent-
ages of total responses. Responses were received from
308 members, of whom 91% indicated that they were
using nitrates for the treatment of patients with CHF
(Figure 1). Most respondents reported using nitrates to
treat patients with CHF with ischemic and nonisch-
emic causes (90% and 81%, respectively), although
more respondents indicated the use of nitrates in
50% of their patients with ischemic compared with
nonischemic causes (43% vs 25%; Figure 2). Nitrates
were used more often in patients with moderate to
severe symptoms (New York Heart Association
[NYHA] classes III and IV) compared with those with
either no or only mild symptoms (NYHA classes I and
II) (Figure 3). Ninety-six percent of respondents re-
ported using nitrates for the reduction of symptoms,
74% for hemodynamic improvement, and 65% for
improved exercise tolerance. Only 14% reported the
use of nitrates for reverse remodeling of the left ven-
tricle (Figure 4).
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